Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy

Gábor Ottóffy, Petra Horváth, Lajos Muth, Alexander Sólyom, M. Garami, Gábor Kovács, T. Nyári, D. Molnár, Gábor Pauler, István Jankovics

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: No examination of simultaneous vaccination against pandemic H1N1 and the seasonal influenza virus strains, in children with cancer receiving chemotherapy, are yet published. We investigated the immunogenicity of a whole-virion, inactivated, adjuvanted pandemic H1N1, and seasonal influenza vaccines administered simultaneously to children with cancer undergoing chemotherapy. Procedure: We prospectively enrolled 27 pediatric patients receiving therapy for various types of cancer. All received influenza vaccination once in a seasonal risk period. We checked hemaglutination-inhibition (HAI) antibody titers in the sera of patients before, and 21-28 days after vaccination. Seroprotective titer was defined as an antibody titer ≥40, and seroresponse as ≥4-fold increase in antibody titers after vaccination. Results: The pre- and post-vaccination seroprotective rates were H1N1: 33-48%, H3N2: 56-78%, B: 0-15% for seasonal influenza, and for pandemic H1N1: 15-37%. The seroresponse rates for seasonal influenza H1N1, H3N2, and B were 22%, 37%, and 22%, respectively, and 30% for the pandemic H1N1 vaccine. Conclusions: Whole-virion, inactivated, adjuvanted vaccine for the pandemic H1N1 Influenza A virus and the seasonal influenza vaccines were found safe and partially immunogenic in children with cancer receiving chemotherapy. The only determinants of responsiveness were lymphocyte count and serum immunoglobulin-G. Only influenza B vaccine elicited significant differences in differences in pre- and post-vaccination seroprotective rates. The response to vaccination for pandemic H1N1 is as effective as other vaccines, however administration of a single vaccine during chemotherapy is more comfortable for pediatric cancer patients. Pediatr Blood Cancer 2014;61:1013-1016.

Original languageEnglish
Pages (from-to)1013-1016
Number of pages4
JournalPediatric Blood and Cancer
Volume61
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Influenza Vaccines
Influenza A virus
Pandemics
Vaccination
Vaccines
Drug Therapy
Human Influenza
Neoplasms
Virion
Antibodies
Pediatrics
H1N1 Subtype Influenza A Virus
Inactivated Vaccines
Lymphocyte Count
Orthomyxoviridae
Serum
Immunoglobulin G

Keywords

  • Chemotherapy
  • Influenza
  • Pandemic H1N1
  • Pediatric oncology
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy. / Ottóffy, Gábor; Horváth, Petra; Muth, Lajos; Sólyom, Alexander; Garami, M.; Kovács, Gábor; Nyári, T.; Molnár, D.; Pauler, Gábor; Jankovics, István.

In: Pediatric Blood and Cancer, Vol. 61, No. 6, 2014, p. 1013-1016.

Research output: Contribution to journalArticle

Ottóffy, Gábor ; Horváth, Petra ; Muth, Lajos ; Sólyom, Alexander ; Garami, M. ; Kovács, Gábor ; Nyári, T. ; Molnár, D. ; Pauler, Gábor ; Jankovics, István. / Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 6. pp. 1013-1016.
@article{f5ced88e7ee442a686eb493d1be1678f,
title = "Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy",
abstract = "Background: No examination of simultaneous vaccination against pandemic H1N1 and the seasonal influenza virus strains, in children with cancer receiving chemotherapy, are yet published. We investigated the immunogenicity of a whole-virion, inactivated, adjuvanted pandemic H1N1, and seasonal influenza vaccines administered simultaneously to children with cancer undergoing chemotherapy. Procedure: We prospectively enrolled 27 pediatric patients receiving therapy for various types of cancer. All received influenza vaccination once in a seasonal risk period. We checked hemaglutination-inhibition (HAI) antibody titers in the sera of patients before, and 21-28 days after vaccination. Seroprotective titer was defined as an antibody titer ≥40, and seroresponse as ≥4-fold increase in antibody titers after vaccination. Results: The pre- and post-vaccination seroprotective rates were H1N1: 33-48{\%}, H3N2: 56-78{\%}, B: 0-15{\%} for seasonal influenza, and for pandemic H1N1: 15-37{\%}. The seroresponse rates for seasonal influenza H1N1, H3N2, and B were 22{\%}, 37{\%}, and 22{\%}, respectively, and 30{\%} for the pandemic H1N1 vaccine. Conclusions: Whole-virion, inactivated, adjuvanted vaccine for the pandemic H1N1 Influenza A virus and the seasonal influenza vaccines were found safe and partially immunogenic in children with cancer receiving chemotherapy. The only determinants of responsiveness were lymphocyte count and serum immunoglobulin-G. Only influenza B vaccine elicited significant differences in differences in pre- and post-vaccination seroprotective rates. The response to vaccination for pandemic H1N1 is as effective as other vaccines, however administration of a single vaccine during chemotherapy is more comfortable for pediatric cancer patients. Pediatr Blood Cancer 2014;61:1013-1016.",
keywords = "Chemotherapy, Influenza, Pandemic H1N1, Pediatric oncology, Vaccine",
author = "G{\'a}bor Ott{\'o}ffy and Petra Horv{\'a}th and Lajos Muth and Alexander S{\'o}lyom and M. Garami and G{\'a}bor Kov{\'a}cs and T. Ny{\'a}ri and D. Moln{\'a}r and G{\'a}bor Pauler and Istv{\'a}n Jankovics",
year = "2014",
doi = "10.1002/pbc.24893",
language = "English",
volume = "61",
pages = "1013--1016",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy

AU - Ottóffy, Gábor

AU - Horváth, Petra

AU - Muth, Lajos

AU - Sólyom, Alexander

AU - Garami, M.

AU - Kovács, Gábor

AU - Nyári, T.

AU - Molnár, D.

AU - Pauler, Gábor

AU - Jankovics, István

PY - 2014

Y1 - 2014

N2 - Background: No examination of simultaneous vaccination against pandemic H1N1 and the seasonal influenza virus strains, in children with cancer receiving chemotherapy, are yet published. We investigated the immunogenicity of a whole-virion, inactivated, adjuvanted pandemic H1N1, and seasonal influenza vaccines administered simultaneously to children with cancer undergoing chemotherapy. Procedure: We prospectively enrolled 27 pediatric patients receiving therapy for various types of cancer. All received influenza vaccination once in a seasonal risk period. We checked hemaglutination-inhibition (HAI) antibody titers in the sera of patients before, and 21-28 days after vaccination. Seroprotective titer was defined as an antibody titer ≥40, and seroresponse as ≥4-fold increase in antibody titers after vaccination. Results: The pre- and post-vaccination seroprotective rates were H1N1: 33-48%, H3N2: 56-78%, B: 0-15% for seasonal influenza, and for pandemic H1N1: 15-37%. The seroresponse rates for seasonal influenza H1N1, H3N2, and B were 22%, 37%, and 22%, respectively, and 30% for the pandemic H1N1 vaccine. Conclusions: Whole-virion, inactivated, adjuvanted vaccine for the pandemic H1N1 Influenza A virus and the seasonal influenza vaccines were found safe and partially immunogenic in children with cancer receiving chemotherapy. The only determinants of responsiveness were lymphocyte count and serum immunoglobulin-G. Only influenza B vaccine elicited significant differences in differences in pre- and post-vaccination seroprotective rates. The response to vaccination for pandemic H1N1 is as effective as other vaccines, however administration of a single vaccine during chemotherapy is more comfortable for pediatric cancer patients. Pediatr Blood Cancer 2014;61:1013-1016.

AB - Background: No examination of simultaneous vaccination against pandemic H1N1 and the seasonal influenza virus strains, in children with cancer receiving chemotherapy, are yet published. We investigated the immunogenicity of a whole-virion, inactivated, adjuvanted pandemic H1N1, and seasonal influenza vaccines administered simultaneously to children with cancer undergoing chemotherapy. Procedure: We prospectively enrolled 27 pediatric patients receiving therapy for various types of cancer. All received influenza vaccination once in a seasonal risk period. We checked hemaglutination-inhibition (HAI) antibody titers in the sera of patients before, and 21-28 days after vaccination. Seroprotective titer was defined as an antibody titer ≥40, and seroresponse as ≥4-fold increase in antibody titers after vaccination. Results: The pre- and post-vaccination seroprotective rates were H1N1: 33-48%, H3N2: 56-78%, B: 0-15% for seasonal influenza, and for pandemic H1N1: 15-37%. The seroresponse rates for seasonal influenza H1N1, H3N2, and B were 22%, 37%, and 22%, respectively, and 30% for the pandemic H1N1 vaccine. Conclusions: Whole-virion, inactivated, adjuvanted vaccine for the pandemic H1N1 Influenza A virus and the seasonal influenza vaccines were found safe and partially immunogenic in children with cancer receiving chemotherapy. The only determinants of responsiveness were lymphocyte count and serum immunoglobulin-G. Only influenza B vaccine elicited significant differences in differences in pre- and post-vaccination seroprotective rates. The response to vaccination for pandemic H1N1 is as effective as other vaccines, however administration of a single vaccine during chemotherapy is more comfortable for pediatric cancer patients. Pediatr Blood Cancer 2014;61:1013-1016.

KW - Chemotherapy

KW - Influenza

KW - Pandemic H1N1

KW - Pediatric oncology

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84901702483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901702483&partnerID=8YFLogxK

U2 - 10.1002/pbc.24893

DO - 10.1002/pbc.24893

M3 - Article

C2 - 24395342

AN - SCOPUS:84901702483

VL - 61

SP - 1013

EP - 1016

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -